Literature DB >> 21503782

[Treatment of crow's feet with two different botulinum toxin type A preparations in split-face technique].

W Prager1, E Wissmüller, B Kollhorst, A Böer, I Zschocke.   

Abstract

BACKGROUND: For the first time, the effectiveness of Xeomin®, and Dysport® in an dose-ratio of 1:3 treating crow's feet (FWS 2-3) was evaluated in a double-blind randomized pilot study. PATIENTS AND
METHOD: Xeomin® (12 units) was compared to Dysport® (36 units) in an intra-individual split-face technique in 22 patients over a period of 4 months. According to the facial-wrinkle-scale (FWS) patients were rated as responders with an improvement of at least 1 point in FWS.
RESULTS: One month after treatment significantly more than 80% of patients were rated as responders. The different products proved to be equivalent in response rate and effectiveness with no significant difference after 4 weeks and 4 months in statistical analysis. Surprisingly the decrease in FWS of crows' feet at rest was more pronounced.
CONCLUSION: The different botulinum toxin type A formulations proved to be equivalent in effectiveness and tolerability in a dose ratio of 1:3 (Xeomin®: Dysport®) The more pronounced decrease of crow's feet at rest points out the importance of muscle insertion into the skin for the cosmetic result in the periorbital region.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21503782     DOI: 10.1007/s00105-011-2148-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  23 in total

1.  Effect of botulinum toxin A on facial wrinkle lines in Koreans.

Authors:  Helen Lew; Young Soo Yun; Sang Yeul Lee; Sung Joo Kim
Journal:  Ophthalmologica       Date:  2002 Jan-Feb       Impact factor: 3.250

Review 2.  Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.

Authors:  Dirk Dressler
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

Review 3.  Pharmacology of therapeutic botulinum toxin preparations.

Authors:  Dirk Dressler; Reiner Benecke
Journal:  Disabil Rehabil       Date:  2007-12-15       Impact factor: 3.033

Review 4.  Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology.

Authors:  Syrus Karsai; Christian Raulin
Journal:  Dermatol Surg       Date:  2008-11-03       Impact factor: 3.398

Review 5.  Botulinum toxin: chemistry, pharmacology, toxicity, and immunology.

Authors:  M F Brin
Journal:  Muscle Nerve Suppl       Date:  1997

6.  The microanatomical basis of facial frown lines.

Authors:  G E Piérard; C M Lapière
Journal:  Arch Dermatol       Date:  1989-08

7.  Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies--therapeutic consequences.

Authors:  H Göschel; K Wohlfarth; J Frevert; R Dengler; H Bigalke
Journal:  Exp Neurol       Date:  1997-09       Impact factor: 5.330

8.  Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet.

Authors:  Nicholas J Lowe; Gary Lask; Paul Yamauchi; Donna Moore
Journal:  J Am Acad Dermatol       Date:  2002-12       Impact factor: 11.527

9.  [Does dilution have an impact on cosmetic results with BoNT/A? Complex-protein-free BoNT/A for treatment of glabella lines].

Authors:  W Prager; I Zschocke; C Reich; L Brocatti; K Henning; V Steinkraus
Journal:  Hautarzt       Date:  2009-10       Impact factor: 0.751

10.  Patient satisfaction with different botulinum toxin type A formulations in the treatment of moderate to severe upper facial rhytids.

Authors:  Koen de Boulle
Journal:  J Cosmet Laser Ther       Date:  2008-06       Impact factor: 2.247

View more
  1 in total

Review 1.  Use of Botulinum Neurotoxin in Ophthalmology.

Authors:  Emel Başar; Ceyhun Arıcı
Journal:  Turk J Ophthalmol       Date:  2016-12-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.